You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長江生命科技(00775.HK):將展示黑色素瘤抗原疫苗免疫療法研究之臨床數據
阿思達克 05-14 08:25
長江生命科技(00775.HK)公布,旗下美國全資附屬公司Polynoma將在美國臨床腫瘤學會(ASCO)於今年5月29日至31日在網上舉行的ASCO20虛擬科學年會上,展示其基於黑色素瘤抗原疫苗免疫療法研究(Melanoma Antigen Vaccine Immunotherapy Study,為seviprotimut-L第三階段臨床研究)B1部分所得臨床數據而作出的最終分析。研究摘要經選定為黑色素瘤/皮膚癌壁報討論環節中進行討論的12項摘要之一。

Polynoma認為黑色素瘤抗原疫苗免疫療法研究B1部分的最終分析,進一步確定去年中期分析的所得結果,顯示使用seviprotimut-L後第二B/二C期黑色素瘤患者(尤其是60歲以下患者及潰瘍病患者)之無復發存活期較長。

在ASCO20虛擬科學年會上展示的數據,乃來自對Polynoma現正進行seviprotimut-L第三階段臨床試驗B1部分所招募347名患者的數據進行的最終分析。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account